NOVO - Semaglutids stærke profil bekræftet i nyt studie
-
Kommentar fra Sydbank:
"Semaglutids stærke profil bekræftet i nyt studie
Vi fastholder 'Køb' på Novo Nordisk. Novo Nordisk offentliggør positive data for
GLP-1 midlet semaglutide, der viser, at midlet er signifikant bedre til at sænke
blodsukkeret og vægten i forhold til Mercks Januvia. Vi fastholder vores
topsalgspotentiale for semaglutide på 18 mia. kr."Læs mere:
https://markets.sydbank.dk/PublicationsWebHandler/Sydbank.aspx?ID=0036696-035002
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind